Clinical Research

CVRx hopes new research will expand access to heart failure therapy
The BENEFIT-HF trial, scheduled to begin enrollment in the months ahead, could significantly increase the number of patients eligible for CVRx's Barostim therapy.
IVL competition heats up as Boston Scientific enters US market
Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.
Coming soon: First-in-human study of gene-modifying drug for hypercholesterolemia
Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.
STEMI cases bring high doses of radiation to the cath lab
“We're so focused on quickly taking care of the patient ... we may be forgetting about radiation safety,” one researcher explained.
New oral contrast agent helps spot 'previously impossible-to-detect' findings on CT
Experts involved in its development are confident the agent has the potential to overcome shortcomings associated with conventional oral agents currently on the market.

CVRx hopes new research will expand access to heart failure therapy

The BENEFIT-HF trial, scheduled to begin enrollment in the months ahead, could significantly increase the number of patients eligible for CVRx's Barostim therapy.

The Boston Scientific Seismiq intravascular lithotripsy (IVL) system entered commercial use in the U.S. in January 2026.

IVL competition heats up as Boston Scientific enters US market

Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.

Gene editing software image from Scribe Therapeutics for its STX-1150 drug to treat LDL-C.

Coming soon: First-in-human study of gene-modifying drug for hypercholesterolemia

Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.

Ryan Madder, MD, Program Director, Interventional Cardiology Fellowship, William Beaumont University Hospital, Corewell Health East, and Michael Abiragi, MD, cardiology fellow, Frederik Meijer Heart and Vascular Institute, Corewell Health West in Grand Rapids, explain a study showing a small number of high dose cases contribute the majority of staff dose, especially STEMI.

STEMI cases bring high doses of radiation to the cath lab

“We're so focused on quickly taking care of the patient ... we may be forgetting about radiation safety,” one researcher explained.

Routine IR procedure could treat endometriosis.

New oral contrast agent helps spot 'previously impossible-to-detect' findings on CT

Experts involved in its development are confident the agent has the potential to overcome shortcomings associated with conventional oral agents currently on the market.

Treating CLTI with atherectomy fails to improve outcomes—is it worth the cost?

Atherectomy is associated with rising healthcare costs, making it important to learn as much about the procedure's long-term value as possible.

Abbott recently announced it is partnering with AtaCor Medical to develop a next-generation extravascular implantable cardioverter defibrillator (EV-ICD) system. AtaCor's investigational extravascular ICD lead will be paired with Abbott's investigational extravascular ICD system.

Abbott works with AtaCor Medical on extravascular ICD system

Extravascular ICDs were developed to avoid complications such as vascular injuries, lead fractures and lead infections. Although rare, these issues can cause serious, life-threatening complications for patients.

CGuard Prime carotid stent system was cleared by the U.S. Food and Drug Administration (FDA) in June 2025.

Pivotal trial highlights safety, effectiveness of FDA-approved carotid stent

The CGuard Prime carotid stent system from InspireMD was approved by the FDA in 2025. These data confirm the device's ability to reduce a patient's stroke risk during treatment.